Viewing Study NCT01038804


Ignite Creation Date: 2025-12-24 @ 9:22 PM
Ignite Modification Date: 2025-12-25 @ 7:09 PM
Study NCT ID: NCT01038804
Status: COMPLETED
Last Update Posted: 2013-09-18
First Post: 2009-12-22
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Sponsor: Astellas Pharma Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module